Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a
Cell and gene therapies are one of the most fast-moving and paradigm-shifting areas in pharmaceutical development today, bringing curative treatments to patients for the first time for cert
Bayer’s network of Co.Lab life sciences incubators has expanded once again with the announcement of a new site in Shanghai, China, that will focus on oncology cell and gen
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.